The content on this site is intended for healthcare professionals only
"Age proved to be the most important factor to undergo - or not undergo - chemotherapy," Dr Markopoulos tells ecancertv at SIOG 2014. He discusses the results of a multidisciplinary survey of 900 physicians in 52 countries, examining the interaction between age and breast cancer screening, diagnosis and outcome.
The survey seems to indicate that physicians are more reluctant to prescribe chemotherapy to geriatric patients, and that elderly patients require more proof of benefit.
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours
Updates on HR-positive HER2-negative breast cancer
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
The role of lymph nodes in stage 3 lung cancer
